Company intelligence / Profile preview

Otonoma

San Diego, California, USAotonoma.com ↗

Ownership: Private
Development stage: Other

Overview

Otonomy developed multiple candidates targeting inner ear disorders using proprietary sustained-release formulations delivered via intratympanic injection. Key programs included OTO‑413 for hearing loss and OTIVIDEX (OTO‑104) for Ménière’s disease, both of which failed in late-stage clinical trials. The company also had an AAV-based gene therapy program in collaboration with AGTC targeting congenital hearing loss. After repeated clinical failures, the company ceased operations in December 2022 and liquidated its assets, some of which were acquired by Spiral Therapeutics.

Therapeutic areas: Rare DiseasesNeurology
Modalities: Small moleculeGene therapyBiologic
Industry: Biotech

Partnerships

AGTC

Beyond the preview

Go deeper on Otonoma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Otonoma.

Explore the full profile